tazobactam has been researched along with ro13-9904 in 23 studies
Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (ro13-9904) | Trials (ro13-9904) | Recent Studies (post-2010) (ro13-9904) |
---|---|---|---|---|---|
1,327 | 153 | 694 | 6,815 | 798 | 2,755 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (30.43) | 18.2507 |
2000's | 7 (30.43) | 29.6817 |
2010's | 4 (17.39) | 24.3611 |
2020's | 5 (21.74) | 2.80 |
Authors | Studies |
---|---|
Jones, R; Satishchandran, V; Shapiro, T; Suh, B; Truant, AL | 1 |
Appelbaum, PC; Jacobs, MR; Pankuch, GA | 1 |
Aldridge, KE; Morice, N; Schiro, DD | 1 |
Hardegger, U; Wüst, J | 1 |
Edelstein, MA; Edelstein, PH | 1 |
Eliopoulos, GM; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C | 1 |
Buxbaum, A; Georgopoulos, A; Graninger, W | 1 |
Amato, R; Andò, F; Azzaro, R; Bellissima, P; Cicciarella, S; Covelli, I; Delia, S; Fogliani, V; Fraschini, F; Girbino, G; Jacoviello, C; Laganà, P; Magrì, M; Maierna, G; Maria, GD; Marone, P; Messina, G; Muscianisi, G; Napoletano, G; Pela, R; Pezza, A; Rizza, S; Rossi, A; Sabato, V; Sanguinetti, C; Tedeschi, D; Varotto, F; Viola, B; Vitale, S | 1 |
Fixson, A; Glasmacher, A; Gorschlüter, M; Hahn, C; Horré, R; Marklein, G; Mey, U; Molitor, E; Sauerbruch, T; Schmidt-Wolf, IG; Ziske, C | 1 |
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
Arora, V; Prakash, SK; Prashad, R; Sharma, VK | 1 |
Carreras, E; Fernández-Avilés, F; Gallego, C; García, L; Gaya, A; González, M; Granell, M; Hernando, A; Martínez, C; Montserrat, E; Ramiro, L; Rovira, M; Segura, S; Urbano-Ispizua, A; Valverde, M | 1 |
Khan, HM; Malik, A; Shahid, M; Shujatullah, F; Shukla, I; Singhai, M; Tahira, F | 1 |
Chen, SW; Liu, XK; Wu, HY; Zhang, LL; Zhang, SC | 1 |
Braun, L; Fairchok, M; Flanagan, R; Mahlen, S; Sainato, R | 1 |
Bailoor, K; Chen, T | 1 |
Gutiérrez-Gutiérrez, B; Kahlmeter, G; Rodríguez-Baño, J | 1 |
Berdaï, D; Boyer, A; Prevel, R | 1 |
Cisera, K; Hughes, C; Rogers, B; Taylor, L; Xie, O | 1 |
Albanell-Fernández, M; Aranda, L; Bartra, J; Gelis, S; González-García, R; López-Cabezas, C; Soy Muner, D | 1 |
Sun, J; Xie, L; Xu, R; Zhu, D | 1 |
Arenere-Mendoza, M; Fernández-de-Gamarra-Martínez, E; Fernández-Polo, A; González-Suárez, S; Gutiérrez-Urbón, JM; Nicolás-Picó, J; Rodríguez-Mateos, ME; Sánchez-Yáñez, E | 1 |
Bautista, J; Beique, L; Cayen, J; Choi, K; Comeau, JL; Conly, J; Dalton, B; Delport, J; Dhami, R; Embree, J; Émond, Y; Evans, G; Frenette, C; Fryters, S; Happe, J; Katz, K; Kibsey, P; Langley, JM; Lee, BE; Lefebvre, MA; Leis, JA; McGeer, A; McKenna, S; Neville, HL; Pelude, L; Rudnick, W; Science, M; Slayter, K; Suh, KN; Thirion, DJG; Tse-Chang, A; Weiss, K | 1 |
3 trial(s) available for tazobactam and ro13-9904
Article | Year |
---|---|
Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Gentamicins; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Treatment Outcome | 2003 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Busulfan; Ceftriaxone; Female; Fever; Health Care Costs; Hematologic Neoplasms; Home Care Services; Hospital Charges; Humans; Inpatients; Male; Middle Aged; Neutropenia; Patient Readmission; Penicillanic Acid; Piperacillin; Stem Cell Transplantation; Tazobactam; Transplantation, Autologous | 2006 |
20 other study(ies) available for tazobactam and ro13-9904
Article | Year |
---|---|
In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefotaxime; Ceftazidime; Ceftriaxone; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Sulbactam; Tazobactam | 1995 |
Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Topics: Ampicillin; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Clavulanic Acids; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Streptococcus pneumoniae; Sulbactam; Tazobactam; Ticarcillin | 1994 |
Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Ceftriaxone; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1994 |
In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Topics: Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactamase Inhibitors; Ceftriaxone; Drug Therapy, Combination; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 1994 |
In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.
Topics: Animals; Ceftriaxone; Cells, Cultured; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Extracellular Space; Guinea Pigs; Intracellular Fluid; Legionella; Legionella pneumophila; Legionnaires' Disease; Macrophages, Alveolar; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis.
Topics: Abdomen; Abscess; Animals; Bacteroides fragilis; Bacteroides Infections; Ceftriaxone; Disease Models, Animal; Drug Therapy, Combination; Male; Penicillanic Acid; Peritoneal Diseases; Rats; Rats, Sprague-Dawley; Tazobactam | 1993 |
Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits.
Topics: Animals; Ceftriaxone; Cephalosporin Resistance; Cephalosporins; Colony Count, Microbial; Diffusion Chambers, Culture; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Rabbits; Tazobactam | 1999 |
An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Disease Susceptibility; Female; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Tazobactam | 2001 |
In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftriaxone; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Hospital Units; In Vitro Techniques; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2005 |
In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Ceftriaxone; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2007 |
[Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Ceftriaxone; Drug Synergism; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2009 |
Severe human parechovirus sepsis beyond the neonatal period.
Topics: Anti-Bacterial Agents; Blood Coagulation Disorders; Ceftriaxone; Enterocolitis, Necrotizing; Enzyme Inhibitors; Fever; Heart Failure; Hepatitis; Humans; Infant; Male; Parechovirus; Penicillanic Acid; Picornaviridae Infections; Piperacillin; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sepsis; Sequence Analysis, RNA; Tazobactam | 2011 |
Fungating groin mass in a woman with a history of follicular lymphoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ceftriaxone; Cyclophosphamide; Diagnosis, Differential; Escherichia coli Infections; Female; Groin; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Penicillanic Acid; Piperacillin; Positron-Emission Tomography; Rituximab; Tazobactam; Tomography, X-Ray Computed; Vincristine | 2017 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2020 |
Evaluation of desensitization protocols to betalactam antibiotics.
Topics: Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Drug Hypersensitivity; Humans; Meropenem; Reproducibility of Results; Retrospective Studies; Review Literature as Topic; Tazobactam | 2022 |
Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftriaxone; Drug Resistance, Bacterial; Enterobacter; Enterobacter cloacae; Humans; Liver Abscess; Microbial Sensitivity Tests; Mutation; Piperacillin; Tazobactam | 2022 |
PAUSATE Study: Prevalence and appropriateness of the use of antimicrobials in Spanish hospitals.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Cross-Sectional Studies; Hospitals; Humans; Meropenem; Piperacillin; Prevalence; Tazobactam | 2022 |
Antimicrobial use among paediatric inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program, 2017/2018.
Topics: Adult; Anti-Infective Agents; Canada; Cefazolin; Ceftriaxone; Child; Cross Infection; Hospitals; Humans; Infant, Newborn; Inpatients; Piperacillin; Tazobactam | 2023 |